Absci is a pioneering AI drug creation company that leverages data-driven approaches to design innovative therapeutics using generative AI. With a state-of-the-art laboratory and headquarters in Vancouver, WA, along with research facilities in New York City, Serbia, and Switzerland, Absci is at the forefront of integrating AI with drug discovery. The company focuses on developing advanced AI models for antibody design and optimization, enabling the creation of biologics that target challenging diseases. Absci fosters a collaborative and multidisciplinary work environment, encouraging its team of AI scientists to translate cutting-edge research into real-world therapeutic solutions.